These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2622860)

  • 1. Hollow fibers as an oral sustained-release delivery system using propranolol hydrochloride.
    Hussain MA; DiLuccio RC; Shefter E; Hurwitz AR
    Pharm Res; 1989 Dec; 6(12):1052-5. PubMed ID: 2622860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hollow fibers as an oral sustained-release delivery system.
    Hussain MA; DiLuccio RC; Shefter E
    Pharm Res; 1989 Jan; 6(1):49-52. PubMed ID: 2717518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluation of a matrix-in-cylinder system for sustained drug delivery.
    Mehuys E; Vervaet C; Gielen I; Van Bree H; Remon JP
    J Control Release; 2004 Apr; 96(2):261-71. PubMed ID: 15081217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and evaluation of a novel delayed-onset sustained-release system of propranolol hydrochloride.
    Feng XM; Ren Q; Zhang WZ; Shen HF; Rong ZX; Fang C; Chen HZ
    J Pharm Pharmacol; 2008 Jul; 60(7):817-22. PubMed ID: 18549667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and in-vitro/in-vivo correlation for propranolol hydrochloride extended-release bead products prepared using aqueous polymeric dispersions.
    Rekhi GS; Jambhekar SS
    J Pharm Pharmacol; 1996 Dec; 48(12):1276-84. PubMed ID: 9004191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations.
    Perucca E; Grimaldi R; Gatti G; Caravaggi M; Crema F; Lecchini S; Frigo GM
    Br J Clin Pharmacol; 1984 Jul; 18(1):37-43. PubMed ID: 6743489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation.
    Marino MR; Dey M; Garg DC; Jallad NS; Dorick DM; Martinez JJ; Weidler DJ
    J Clin Pharmacol; 1987 Nov; 27(11):885-91. PubMed ID: 3429696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained propranolol delivery and increased oral bioavailability in dogs given a propranolol Laurate salt.
    Aungst BJ; Hussain MA
    Pharm Res; 1992 Nov; 9(11):1507-9. PubMed ID: 1475241
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioavailability of sustained release propranolol formulations.
    McAinsh J; Baber NS; Holmes BF; Young J; Ellis SH
    Biopharm Drug Dispos; 1981; 2(1):39-48. PubMed ID: 7236870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.
    Byrne AJ; McNeil JJ; Harrison PM; Louis W; Tonkin AM; McLean AJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):45S-50S. PubMed ID: 6743474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral sustained-release suspension based on a novel taste-masked and mucoadhesive carrier-ion-exchange fiber.
    Yuan J; Liu T; Li H; Shi T; Xu J; Liu H; Wang Z; Wang Q; Xu L; Wang Y; Li S
    Int J Pharm; 2014 Sep; 472(1-2):74-81. PubMed ID: 24882038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of a new sustained release preparation of propranolol in normal healthy volunteers.
    Biswas NR; Garg SK; Lal R; Kumar N; Gyawali K; Narendranath KA; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):436-8. PubMed ID: 3198297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core.
    Mehuys E; Remon JP; Korst A; Van Bortel L; Mols R; Augustijns P; Porter C; Vervaet C
    J Control Release; 2005 Oct; 107(3):523-36. PubMed ID: 16055224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and in vitro/in vivo evaluation of sustained-release venlafaxine hydrochloride pellets.
    Liu Y; Sun Y; Sun J; Zhao N; Sun M; He Z
    Int J Pharm; 2012 Apr; 426(1-2):21-28. PubMed ID: 22266529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits.
    Rao PR; Reddy MN; Ramakrishna S; Diwan PV
    Eur J Pharm Biopharm; 2003 Jul; 56(1):81-5. PubMed ID: 12837485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal absorption of propranolol from different dosage forms by rats and dogs.
    Hussain A; Hirai S; Bawarshi R
    J Pharm Sci; 1980 Dec; 69(12):1411-3. PubMed ID: 7463327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluations of a novel pulsed and controlled osmotic pump capsule.
    Zhang W; Zhang L; Qu X; Zhu Z; Pan Y; Guan J; Pan W
    Drug Dev Ind Pharm; 2015 Feb; 41(2):322-32. PubMed ID: 24295490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a polyvinyl alcohol hydrogen containing phospholipid as controlled-release vehicle for rectal administration of (+/-)-propranolol HCl.
    Morimoto K; Fukanoki S; Hatakeyama Y; Nagayasu A; Morisaka K; Hyon SH; Ikada Y
    J Pharm Pharmacol; 1990 Oct; 42(10):720-2. PubMed ID: 1982145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma propranolol levels in beagle dogs after administration of propranolol hemisuccinate ester.
    Garceau Y; Davis I; Hasegawa J
    J Pharm Sci; 1978 Oct; 67(10):1360-3. PubMed ID: 702279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.